A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Completed · Phase 3 · NCT02181413
Conditions: Multiple Myeloma, Autologous Stem Cell Transplant
At a glance
- Research payments reported, 2025
- $985
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 656
About the trial
- Sponsor
- Takeda
- Tested
- Ixazomib Citrate (drug), Placebo (drug)
- Dates
- Started 2014-07-16; completion 2023-09-08
- Results posted
- Yes
The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
From ClinicalTrials.gov, last updated 2024-11-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $985 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Baylor Research Institute $985
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.